Drug Profile
Tretazicar/caricotamide
Alternative Names: CB 1954; EP 0152R; ProlarixLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Protherics
- Developer BTG
- Class Antineoplastics; Aziridines
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Liver cancer
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 16 Sep 2009 Discontinued - Phase-II for Liver cancer in Belgium (IV)
- 06 May 2009 Tretazicar/caricotamide is available for licensing in (http://www.btgplc.com)